Draft Discussion Points and Questions to the Committee

First Page		Document Content
Amgen Growth factors Radiobiology Filgrastim Chemotherapy Effective dose Bone marrow suppression Medical imaging Medicine Hematology Oncology		Draft Discussion Points and Questions to the Committee Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 77,79 KB Share Document on Facebook

	BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi DocID: 1rrNB - View Document
	Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20 DocID: 1q6vz - View Document
	“You Don’t Know What You’re Missing” Evaluating Competitor Clinical Trials with the BizInt Smart Charts Product Family November 2013 DocID: 1mfkn - View Document
	[ Industry Watch ] INDIA Intas Plans Filgrastim launch in North America, Europe DocID: 1kixC - View Document
	SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib, Temozolomid DocID: 1fBTU - View Document